プロパティ

安全情報

説明

CHF-1301 was launched as an injection in Italy for the treatment of patients with Parkinson's disease, particularly those with complications in their clinical responses. CHF-1301 is the methyl ester of L-Dopa (levodopa), the immediate precursor of dopamine. Thus, this prodrug is more soluble in water at physiological pH, better absorbed and slowly transformed into levodopa in vivo; it consequently improves the duration of action and prevents the rapid fluctuations in response or involontary movements (dyskinesia) observed during chronic treatment with levodopa. In patients with a delayed effect of levodopa (on-phenomenon) or a severe resistance to L-Dopa (off-phenomenon), CHF- 1301 significantly improves the onset and the stability of the'response.